Please login to the form below

Not currently logged in
Email:
Password:

Pfizer drives oncology R&D growth

Pfizer is to run seven new clinical studies into liver, renal cell carcinoma, lung and prostate cancers
Pfizer is to run seven new clinical studies into liver, renal cell carcinoma, lung and prostate cancers.

These studies are part of Pfizer's growing oncology research and development (R&D) programme, which has increased by 400 per cent since 2003. Dedicating just under a quarter of its overall R&D budget to oncology, the company currently has 22 compounds in 232 clinical studies.

"We are seeing our sustained efforts in oncology mature as our development programmes continue to advance into late-stage clinical trials," said Dr Charles Baum, vice-president of Pfizer Global Research and Development.

In 2008 alone, Pfizer has presented 299 new agents at the American Society of Clinical Oncology (ASCO) meeting. The company has also started two phase III studies and expects to start the remaining five by the end of the year.

A dedicated business unit, focused on oncology within Pfizer's worldwide pharmaceutical group, was established in March 2008. The unit will accelerate the launches of new oncology agents and focus research efforts on cancers common in Asia such as those of the liver, oesophagus and nasopharynx.

4th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics